Is phenomenology the best approach to health research?

American Journal of Epidemiology

Volumn 166, Issue 10, 2007, Pages 1109-1115

  Kuller, Lewis ^a  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Behavioral research; Biological phenomena; Delivery of health care; National Institutes of Health (U.S.); Research; Systems biology; Technology

Indexed keywords

DISEASE INCIDENCE; HEALTH CARE; INTEGRATED APPROACH; PHILOSOPHY; PUBLIC HEALTH; RESEARCH INSTITUTION; RESEARCH WORK;

HEALTH CARE ORGANIZATION; INCUBATION TIME; MEDICAL RESEARCH; PHENOMENOLOGY; REVIEW; SOCIAL BEHAVIOR;

BIOMEDICAL RESEARCH; EPIDEMIOLOGIC METHODS; GENOMICS; HUMANS; PRIMARY PREVENTION;

EID: 35648984140     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwm258     Document Type: Review

References (66)

1. Zerhouni EA. The NIH roadmap. Science 2003;302:63-72.
2. Culliton BJ. Extracting knowledge from science: a conversation with Elias Zerhouni. Health Aff (Millwood) 2006;25:w94-103.
3. Phenomenology. Stedman's medical dictionary, 27th ed. Baltimore, MD: Lippincott Williams & Wilkins, 2000;1363.
4. Marks AR. Rescuing the NIH before it is too late. J Clin Invest 2006;116:844-5.
5. Stolovitzky G, Califano A. Systems biology. Making sense of oceans of biological data. Update (The New York Academy of Sciences Magazine), March/April 2006:20-3.
6. Masotti PJ, Fick R, Johnson-Masotti A, et al. Healthy naturally occurring retirement communities: a low-cost approach to facilitating healthy aging. Am J Public Health 2006;96:1164-70.
7. Haines A, Kovats RS, Campbell-Lendrum D, et al. Climate change and human health: impacts, vulnerability, and mitigation. Lancet 2006;367:2101-9. (Erratum published in Lancet 2006;368:646).
8. Marmot M. Health in an unequal world. Lancet 2006;368:2081-94.
9. Sorlie P, Rogot E, Anderson R, et al. Black-white mortality differences by family income. Lancet 1992;340:346-50.
10. Murray CJL, Kulkarni SC, Michaud C, et al. Eight Americas: investigating mortality disparities across races, counties, and race-counties in the United States. PLoS Med 2006;3:1513-24.
11. Muennig P, Sohler N, Mahato B. Socioeconomic status as an independent predictor of physiological biomarkers of cardiovascular disease: evidence from NHANES. Prev Med 2007;45:35-40.
12. Epel ES, Blackburn EH, Lin J, et al. Accelerated telomere shortening in response to life stress. Proc Natl Acad Sci U S A 2004;101:17312-15.
13. Warne JP, Dallman MF. Stress, diet and abdominal obesity: Y? Nat Med 2007;13:781-3.
14. Christakis NA, Fowler JH. The spread of obesity in a large social network over 32 years. N Engl J Med 2007;357:370-9.
15. Gregersen PK. Modern genetics, ancient defenses, and potential therapies. N Engl J Med 2007;356:1263-6.
16. Wong TY, Liew G, Mitchell P. Clinical update: new treatments for age-related macular degeneration. Lancet 2007;370:204-5.
17. Schiffer CA. BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med 2007;357:258-65.
18. The Warfarin Antiplatelet Vascular Evaluation Trial Investigators, Anand S, Yusuf S, et al. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 2007;357:217-27.
19. Stolley PD, Lasky T. Investigating disease patterns. The science of epidemiology. New York, NY: Scientific American Library, 1995.
20. Lenfant C. Shattuck lecture-clinical research to clinical practice - lost in translation? N Engl J Med 2003;349:868-74.
21. Keys A, ed. Coronary heart disease in seven countries. New York, NY: American Heart Association, 1970. (Monograph 29).
22. McGill HC, ed. The geographic pathology of atherosclerosis. Baltimore, MD: Williams & Wilkins, 1968.
23. Stamler J, Shekelle R. Dietary cholesterol and human coronary heart disease. The epidemiologic evidence. Arch Pathol Lab Med 1988;112:1032-40.
24. Goldstein JL, Brown MS. The LDL receptor defect in familial hypercholesterolemia. Implications for pathogenesis and therapy. Med Clin North Am 1982;66:335-62.
25. Dahl LK, Leitl G, Heine M. Influence of dietary potassium and sodium/potassium molar ratios on the development of salt hypertension. J Exp Med 1972;136:318-30.
26. Stamler R. The primary prevention of hypertension and the population blood pressure problem. In: Marmot M, Elliott P, eds. Coronary heart disease epidemiology: from etiology to public health. New York, NY: Oxford University Press, 1992:415-34.
27. He J, Whelton PK, Appel LJ, et al. Effect of modest salt reduction on blood pressure: a meta-analysis of randomized trials. Implications for public health. J Hum Hypertens 2002;16:761-70.
28. Lifton RP. Genetic dissection of human blood pressure variation: common pathways from rare phenotypes. Harvey Lect 2006;100:71-99.
29. Williams AO, Loewenson RB, Lippert DM, et al. Cerebral atherosclerosis and its relationship to selected diseases in Nigerians: a pathological study. Stroke 1975;6:395-401.
30. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72.
31. Greenland P, Knoll MD, Stamler J, et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA 2003;290:891-7.
32. Stamler J. Low risk - and the "no more than 50%" myth/dogma. Arch Intern Med 2007;167:537-9.
33. Francis T Jr, Korns RF, Voight RB, et al. An evaluation of the 1954 poliomyelitis vaccine trials. Am J Public Health 1955;45:1-63.
34. Sheps MC. Shall we count the living of the dead. N Engl J Med 1958;259:1210-14.
35. Leon DA. Liver cirrhosis mortality rates in Britain from 1950 to 2002: an analysis of routine data. Lancet 2006;367:52-6.
36. Lloyd-Jones DM. Short-term versus long-term risk for coronary artery disease: implications for lipid guidelines. Curr Opin Lipidol 2006;17:619-25.
37. Kuller LH, Arnold AM, Psaty BM, et al. 10-year follow-up of subclinical cardiovascular disease and risk of coronary heart disease in the Cardiovascular Health Study. Arch Intern Med 2006;166:71-8.
38. Freedman ML, Haiman CA, Patterson N, et al. Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci U S A 2006;103:14068-73.
39. Pollex RL, Hegele RA. Copy number variation in the human genome and its implications for cardiovascular disease. Circulation 2007;115:3130-8.
40. Easton DF, Pooley KA, Dunning AM, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007;447:1087-93.
41. Topol EJ, Murray SS, Frazer KA. The genomics gold rush. JAMA 2007;298:218-21.
42. Maller J, George S, Purcell S, et al. Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration. Nat Genet 2006;38:1055-9.
43. Turner ST, Schwartz GL, Boerwinkle E. Personalized medicine for high blood pressure. Hypertension 2007;50:1-5.
44. Ware JH. The limitations of risk factors as prognostic tools. N Engl J Med 2006;355:2615-17.
45. Janssens AC, van Duijn CM. Towards predictive genetic testing of complex diseases. Eur J Epidemiol 2006;21:869-70.
46. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992;152:56-64.
47. Rose G, Day S. The population mean predicts the number of deviant individuals. BMJ 1990;301:1031-4.
48. Dickinson BD, Havas S; Council on Science and Public Health, American Medical Association. Reducing the population burden of cardiovascular disease by reducing sodium intake: a report of the Council on Science and Public Health. Arch Intern Med 2007;167:1460-8.
49. Janssens AC, Gwinn M, Valdez R, et al. Predictive genetic testing for type 2 diabetes. BMJ 2006;333:509-10.
50. Franceschi C, Capri M, Monti D, et al. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev 2007;128:92-105.
51. Le Souef PN, Goldblatt J, Lynch NR. Evolutionary adaptation of inflammatory immune responses in human beings. Lancet 2000;356:242-4.
52. Ness RB. The consequences for human reproduction of a robust inflammatory response. Q Rev Biol 2004;79:383-93.
53. Krause DS, Van Etten RA. Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005;353:172-87.
54. Shiffman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007;357:124-34.
55. Jubb AM, Oates AJ, Holden S, et al. Predicting benefit from anti-angiogenic agents in malignancy. Nat Rev Cancer 2006;6:626-35.
56. Kolonel LN, Altshuler D, Henderson BE. The multiethnic cohort study: exploring genes, lifestyle and cancer risk. Nat Rev Cancer 2004;4:1-9.
57. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006;118:3030-44.
58. Schwartz D, Collins F. Environmental biology and human disease. Science 2007;316:695-6.
59. Phillipson EA. If it's not integrative, it may not be translational. Clin Invest Med 2002;25:94-6.
60. Wild CP. Complementing the genome with an "exposome": the outstanding challenge of environmental exposure measurement in molecular epidemiology. Cancer Epidemiol Biomarkers Prev 2005;14:1847-50.
61. Maruvada P, Srivastava S. Joint National Cancer Institute-Food and Drug Administration workshop on research strategies, study designs, and statistical approaches to biomarker validation for cancer diagnosis and detection. Cancer Epidemiol Biomarkers Prev 2006;15:1078-82.
62. Arnett DK, Baird AE, Barkley RA, et al. Relevance of genetics and genomics for prevention and treatment of cardiovascular disease. A scientific statement from the American Heart Association Council on Epidemiology and Prevention, the Stroke Council, and the Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 2007;115:2878-901.
63. Ness RB, Koopman JS, Roberts MS. From the American College of Epidemiology Annual Meeting 2006. Causal system modeling in chronic disease epidemiology. Ann Epidemiol 2007;17:564-8.
64. Thomas DC. The need for a systematic approach to complex pathways in molecular epidemiology. Cancer Epidemiol Biomarkers Prev 2005;14:557-9.
65. Kuller LH. Hyperlipidemia and cardiovascular disease. Curr Opin Lipidol 2007;18:230-3.
66. Schottenfeld D, Beebe-Dimmer J. Alleviating the burden of cancer: a perspective on advances, challenges, and future directions. Cancer Epidemiol Biomarkers Prev 2006;15:2049-55.